Leadership of the ACAAI Advocacy Council attended this year’s FDA Annual Compounding Listening Session last week to continue to keep up with the topic and protect allergists’ ability to mix allergen extracts in their offices.
Representing the College were James Sublett, MD, FACAAI, executive director of advocacy and government affairs, J. Allen Meadows, MD, FACAAI, associate director of advocacy and government affairs, and Leela Baggett, legal counsel to the Advocacy Council.
These meetings allow the Advocacy Council to hear about current and future concerns the FDA has about compounding and how those concerns might affect mixing allergen extracts. A number of compounding topics were discussed, including the marketing of IV rehydration clinics. Presentations were made by dermatology and ophthalmology. Fortunately, nothing new regarding mixing of allergen extracts was discussed.
The Advocacy Council continues to encourage all members to follow the allergen specific USP guidelines.
The Advocacy Council – ADVOCATING FOR ALLERGISTS AND THEIR PATIENTS.
